- Home
- TNXP vs POWW Comparison
TNXP vs POWW Comparison
Compare TNXP & POWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- POWW
- Stock Information
- Founded
- TNXP 2007
- POWW 1990
- Country
- TNXP United States
- POWW United States
- Employees
- TNXP N/A
- POWW N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- POWW Ordnance And Accessories
- Sector
- TNXP Health Care
- POWW Industrials
- Exchange
- TNXP Nasdaq
- POWW Nasdaq
- Market Cap
- TNXP 207.5M
- POWW 219.7M
- IPO Year
- TNXP N/A
- POWW N/A
- Fundamental
- Price
- TNXP $39.78
- POWW $1.45
- Analyst Decision
- TNXP Strong Buy
- POWW Hold
- Analyst Count
- TNXP 2
- POWW 1
- Target Price
- TNXP $585.00
- POWW $1.50
- AVG Volume (30 Days)
- TNXP 1.3M
- POWW 544.4K
- Earning Date
- TNXP 05-12-2025
- POWW 05-20-2025
- Dividend Yield
- TNXP N/A
- POWW N/A
- EPS Growth
- TNXP N/A
- POWW N/A
- EPS
- TNXP N/A
- POWW N/A
- Revenue
- TNXP $10,041,000.00
- POWW $125,989,192.00
- Revenue This Year
- TNXP $12.17
- POWW $5.67
- Revenue Next Year
- TNXP $789.15
- POWW N/A
- P/E Ratio
- TNXP N/A
- POWW N/A
- Revenue Growth
- TNXP N/A
- POWW N/A
- 52 Week Low
- TNXP $6.76
- POWW $0.95
- 52 Week High
- TNXP $558.08
- POWW $2.86
- Technical
- Relative Strength Index (RSI)
- TNXP 74.56
- POWW 30.31
- Support Level
- TNXP $25.40
- POWW $1.61
- Resistance Level
- TNXP $37.84
- POWW $1.78
- Average True Range (ATR)
- TNXP 4.17
- POWW 0.10
- MACD
- TNXP 1.75
- POWW -0.06
- Stochastic Oscillator
- TNXP 87.00
- POWW 2.40
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About POWW AMMO Inc.
AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.